These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33592502)
21. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971 [TBL] [Abstract][Full Text] [Related]
22. APOBEC3A is a prominent cytidine deaminase in breast cancer. Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499 [TBL] [Abstract][Full Text] [Related]
32. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Serebrenik AA; Starrett GJ; Leenen S; Jarvis MC; Shaban NM; Salamango DJ; Nilsen H; Brown WL; Harris RS Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22158-22163. PubMed ID: 31611371 [TBL] [Abstract][Full Text] [Related]
33. Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers. Argyris PP; Wilkinson PE; Jarvis MC; Magliocca KR; Patel MR; Vogel RI; Gopalakrishnan R; Koutlas IG; Harris RS Mod Pathol; 2021 Feb; 34(2):280-290. PubMed ID: 32632179 [TBL] [Abstract][Full Text] [Related]
34. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441 [TBL] [Abstract][Full Text] [Related]
35. Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B. Shi K; Demir Ö; Carpenter MA; Wagner J; Kurahashi K; Harris RS; Amaro RE; Aihara H Sci Rep; 2017 Dec; 7(1):17415. PubMed ID: 29234087 [TBL] [Abstract][Full Text] [Related]
36. Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6. Mori S; Takeuchi T; Ishii Y; Kukimoto I Biochem Biophys Res Commun; 2015 May; 460(3):555-60. PubMed ID: 25800874 [TBL] [Abstract][Full Text] [Related]
37. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Cescon DW; Haibe-Kains B; Mak TW Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878 [TBL] [Abstract][Full Text] [Related]
38. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727 [TBL] [Abstract][Full Text] [Related]
39. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers. Chou WC; Chen WT; Hsiung CN; Hu LY; Yu JC; Hsu HM; Shen CY Sci Rep; 2017 Mar; 7():44089. PubMed ID: 28276478 [TBL] [Abstract][Full Text] [Related]
40. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations. Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]